Eisai

News

Merck gets a leg-up for Keytruda in first-line kidney cancer

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the increasingly competitive first-line kidney cancer market.

News

Closeup of X-ray photography of human brain

Could Lilly’s donanemab readout in Alzheimer's boost Biogen’...

When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a rare win for the amyloid hypothesis, although there’s no shortage of candidates tha

News

Merck & Co/Eisai eye kidney cancer use for immunotherapy com...

Merck & Co and Eisai are to file results from a phase 3 trial testing a combination of the former’s immunotherapy Keytruda, combined with the latter’s cancer drug Lenvima in untreated p

News

Gilead's rheumatoid arthritis pill approved in Japan

Gilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted it a licence following an FDA rejection in August.

News

Has-pharma-been-too-slow-to-respond-to-coronavirus

Japan trials app to help coronavirus patients recover at hom...

A smartphone app developed by medical software specialist Allm is being trialled in Japan to see if it can help patients with milder coronavirus symptoms recuperate at home, wi

News

Biogen and Eisai trial drug in asymptomatic Alzheimer's dise...

Biogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but with elevated levels of amyloid in their brains, the protein aggr

Merck gets a leg-up for Keytruda in first-line kidney cancer

Could Lilly’s donanemab readout in Alzheimer's boost Biogen’...

Merck & Co/Eisai eye kidney cancer use for immunotherapy com...

Gilead's rheumatoid arthritis pill approved in Japan

Japan trials app to help coronavirus patients recover at hom...

Biogen and Eisai trial drug in asymptomatic Alzheimer's dise...

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

Eisai

Editor's Picks